Bahram G. Kermani

TL;DR: The analytic and clinical validation of the gene panel are reported and near-perfect analytic specificity enables complete coverage of many genes without the false positives typically seen with traditional sequencing assays at mutant allele frequencies or fractions below 5%.

TL;DR: In this article, a set of methods for generating and applying therapeutic interventions for cancer cells from a subject are described. But none of the methods are suitable for the analysis of tumor heterogeneity.

TL;DR: In this article, the authors present systems and methods to detect somatic or germline variants by providing a predetermined genomic DNA (gDNA) to an assay mixture, and capturing a sample of a subject's genetic information using a DNA sequencer and detecting genetic variants from the genetic information.

TL;DR: In this paper, a set of methods are described for determining gene fusion by determining a fused read containing sequencing data of a portion of a fused chromosome DNA molecule, determining a predetermined point on the genome with at least one mapped portion of the fused read clipped at the predetermined point (a breakpoint), identifying two mapped read portions from two breakpoints (breakpoint pair) as a potential fusion candidate, creating one or more fusion sets based on breakpoint pairs and clustering the fusion sets into one or multiple fusion clusters, and identifying each fusion cluster meeting a predetermined criterion as a gene

TL;DR: Comprehensive sequencing of a patient9s cancer in real -time through a simple blood test can empower oncologists to make better informed treatment decisions, especially when repeat tissue biopsy is not a desirable or viable option.